

Fresenius Kabi Canada Ltd.

165 Galaxy Blvd, Suite 100 Toronto, Ontario Canada M9W 0C8 T: 905.770.3711

F: 844.513.1522 W: fresenius-kabi.ca

March 31, 2023

Midazolam and Tobramycin Availability Notice

Dear Valued Customer.

Fresenius Kabi Canada is pleased to advise that our **Midazolam Injection 5 mg/mL MD Vial 2 mL** will be available at Ontario distribution centres by **April 6, 2023**, and at all other distribution centres by **April 11, 2023**. Once available, this product will be available to all customers with no restrictions.

Our Tobramycin Injection 40 mg/mL MD Vial 30 mL will be available at Ontario distribution centres by April 6, 2023, and at all other distribution centres by April 11, 2023. Once available, this product will be placed on allocation. Contract customers will be allocated 100% of historical monthly demand of the 30 mL plus substitution coverage at 50% of historical monthly demand of Tobramycin for Injection 1.2 g PBP Vial 50 mL at a 1:1 ratio.

DIN	Fresenius Kabi Product Code	MDP Product Code	McKesson Product Code	Product Description	Availability Date
02242905	C410202	922572	23015	Midazolam Injection 5 mg/mL MD Vial 2 mL	Ontario distribution centres by: Apr. 6, 2023 At all other distribution centres by: Apr. 11, 2023
02230640	C300630	922894	54241	Tobramycin Injection 40 mg/mL MD Vial 30 mL	Ontario distribution centres by: Apr. 6, 2023 At all other distribution centres by: Apr. 11, 2023

Thank you for your patience and understanding during our supply interruption and please do not hesitate to contact your sales representative with any questions or concerns.

Sincerely,

Joseph Le

Senior Manager, Commercial Operations & Analytics

joseph.le@fresenius-kabi.com